Proteomics Analysis for Recognition of Acute Cellular Rejection After Lung Transplantation

NCT ID: NCT00558597

Last Updated: 2011-07-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-03-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients with acute rejection after lung transplantation the peptide profile in broncho-alveolar lavage (BAL) and urine should be compared in order to identify a paradigm that allows an non-invasive rejection therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Goal of the study is the establishment of biomarkers for early diagnosis of acute rejection, followed by a late validation of the paradigm with prospectively collected samples, which will be examined blinded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rejection Lung Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

30 patients with stable graft function

No interventions assigned to this group

2

30 patients with acute rejection after lung transplantation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with stable graft function
* Patients with acute rejection

Exclusion Criteria

* Acute infection
* BOS
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hannover Medical School

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Medical School

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jens Gottlieb, Dr. med.

Role: PRINCIPAL_INVESTIGATOR

Hannover Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hannover Medical School

Hanover, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jens Gottlieb, Dr. med.

Role: CONTACT

+49-511-5320 ext. 3560

Isabelle Bodmann

Role: CONTACT

+49-511-5320 ext. 2667

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jens Gottlieb, Dr. med.

Role: primary

+49-511-5320 ext. 3560

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

154

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.